Article Text

Download PDFPDF

Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study
Free
  1. A Galor,
  2. C L Karp,
  3. S Chhabra,
  4. S Barnes,
  5. E C Alfonso
  1. Bascom Palmer Eye Institute, University of Miami, Miami, Florida, USA
  1. Correspondence to Dr C L Karp, Bascom Palmer Eye Institute, 900 NW 17 Street, Miami, FL 33136, USA; ckarp{at}med.miami.edu

Abstract

Background/aims To compare the effectiveness and side-effect profile of two doses of interferon alpha2b (IFNα2b) eye-drops (1 million international units (IU)/ml versus 3 million IU/ml) in the treatment of ocular surface squamous neoplasia (OSSN).

Methods Retrospective case series.

Results Thirty-five eyes were identified over an 11-year period (1996–2007). Twenty-one eyes (19 patients) with conjunctival intraepithelial neoplasia (CIN) were treated with 1 million IU/ml of topical IFN-α2b; 12 eyes (nine patients) with CIN were treated with 3 million IU/ml. Two patients with squamous cell carcinoma (SCC) were treated with topical interferon, one with 1 million IU/ml and one with 3 million IU/ml. Baseline demographic information was not statistically different between the two groups. In patients with CIN, topical therapy eliminated disease in 81% of eyes in the 1 million IU/ml group versus 92%, in the 3 million IU/ml group, p=0.41. The median time to OSSN resolution was 2.8 months in the 1 million IU/ml group and 1.9 months in the 3 million IU/ml group, p=0.55. Neither eye with SCC responded to interferon therapy. Topical therapy was well tolerated. After a median follow-up of 24 months, three recurrences were seen in eyes successfully treated with topical therapy.

Conclusion In our study, there were no significant differences between the 1 million IU/ml group and the 3 million IU/ml group for the treatment of CIN.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Funding Unrestricted funds from Research to Prevent Blindness.

  • Competing interests None.

  • Ethics approval Ethics approval was provided by University of Miami Institutional Review Board.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • Review
    Ricardo Sepulveda Jacob Pe'er Edoardo Midena Stefan Seregard Harminder S Dua Arun D Singh
  • At a glance
    Harminder S Dua Arun D Singh